← All trials
NCT04939441
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 20, 2021
- Primary completion
- May 1, 2024
- Completion date
- May 1, 2025
- First posted
- Jun 25, 2021
- Last posted
- Jun 25, 2021
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Capital Medical UniversityLead sponsor
- Capital Medical UniversityOverall official - principal investigator
- Capital Medical UniversitySponsor investigator
- Fudan UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Tianjin Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Shanghai University of Traditional Chinese MedicineCollaborator
- Tianjin Second People's HospitalCollaborator
- The Sixth People's Hospital of ZhengzhouCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.